Nuvation Fast Track Designation to investigational IDH1 inhibitor safusidenib for IDH1-mutant glioma
Nuvation Bio announces that the FDA has granted Fast Track Designation to its investigational IDH1 inhibitor safusidenib for the treatment of IDH1-mutant glioma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.